WO2006067635A3 - USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT - Google Patents

USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT Download PDF

Info

Publication number
WO2006067635A3
WO2006067635A3 PCT/IB2005/004092 IB2005004092W WO2006067635A3 WO 2006067635 A3 WO2006067635 A3 WO 2006067635A3 IB 2005004092 W IB2005004092 W IB 2005004092W WO 2006067635 A3 WO2006067635 A3 WO 2006067635A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine adjuvant
lymphocyte
lymphocyte activators
ϝδt
activators
Prior art date
Application number
PCT/IB2005/004092
Other languages
French (fr)
Other versions
WO2006067635A2 (en
Inventor
Emanuelle Trannoy
Nicolas Burdin
Original Assignee
Innate Pharma Sa
Emanuelle Trannoy
Nicolas Burdin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma Sa, Emanuelle Trannoy, Nicolas Burdin filed Critical Innate Pharma Sa
Publication of WO2006067635A2 publication Critical patent/WO2006067635A2/en
Publication of WO2006067635A3 publication Critical patent/WO2006067635A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

The present invention is directed to the use of a ϜδT lymphocyte activator, particularly phosphoantigen compounds, as vaccine adjuvant to promote and enhance antigen specific immunological responses, as well as antigen-based vaccines composition comprising a ϜδT lymphocyte activator.
PCT/IB2005/004092 2004-12-20 2005-12-19 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT WO2006067635A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63761904P 2004-12-20 2004-12-20
US60/637,619 2004-12-20

Publications (2)

Publication Number Publication Date
WO2006067635A2 WO2006067635A2 (en) 2006-06-29
WO2006067635A3 true WO2006067635A3 (en) 2006-08-24

Family

ID=36498714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004092 WO2006067635A2 (en) 2004-12-20 2005-12-19 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT

Country Status (1)

Country Link
WO (1) WO2006067635A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782721B1 (en) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med NOVEL PHOSPHOHALOHYDRIN COMPOUNDS, MANUFACTURING METHOD AND APPLICATIONS
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020673A1 (en) * 1994-01-28 1995-08-03 Centre National De La Recherche Scientifique (C.N.R.S.) Organo-phosphorus compounds as activators of gamma delta t cells
WO2000012519A1 (en) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphoepoxides, method for making same and uses
WO2000012516A1 (en) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphohalohydrins, method for making same and uses
DE10134705A1 (en) * 2001-07-20 2003-02-06 Jomaa Pharmaka Gmbh New acyclic or cyclic organophosphorus compounds, are gamma-delta-T cell activators useful e.g. as medicaments for treating asthma, chronic bronchitis, ulcerative colitis, autoimmune diseases or allergies
WO2003009855A2 (en) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorous compounds for activating gamma/delta t cells
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
WO2003050128A1 (en) * 2001-12-11 2003-06-19 Laboratoire Mayoly Spindler Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
WO2003070921A1 (en) * 2002-02-22 2003-08-28 Innate Pharma METHODS FOR PRODUCING Ϝδ T CELLS
US6624151B1 (en) * 1999-04-06 2003-09-23 Institut National De La Sante Et De La Recherche Medicale Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
EP1426052A1 (en) * 2002-12-02 2004-06-09 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
WO2005102385A1 (en) * 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020673A1 (en) * 1994-01-28 1995-08-03 Centre National De La Recherche Scientifique (C.N.R.S.) Organo-phosphorus compounds as activators of gamma delta t cells
WO2000012519A1 (en) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphoepoxides, method for making same and uses
WO2000012516A1 (en) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphohalohydrins, method for making same and uses
US6624151B1 (en) * 1999-04-06 2003-09-23 Institut National De La Sante Et De La Recherche Medicale Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
DE10134705A1 (en) * 2001-07-20 2003-02-06 Jomaa Pharmaka Gmbh New acyclic or cyclic organophosphorus compounds, are gamma-delta-T cell activators useful e.g. as medicaments for treating asthma, chronic bronchitis, ulcerative colitis, autoimmune diseases or allergies
WO2003009855A2 (en) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorous compounds for activating gamma/delta t cells
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
WO2003050128A1 (en) * 2001-12-11 2003-06-19 Laboratoire Mayoly Spindler Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
WO2003070921A1 (en) * 2002-02-22 2003-08-28 Innate Pharma METHODS FOR PRODUCING Ϝδ T CELLS
EP1426052A1 (en) * 2002-12-02 2004-06-09 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
WO2005102385A1 (en) * 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEML L ET AL: "IMMUNOSTIMULATORY CPG MOTIFS TRIGGER A T HELPER-1 IMMUNE RESPONSE TO HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) GP160 ENVELOPE PROTEINS", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, WALTER DE GRUYTER UND CO, DE, vol. 37, no. 3, March 1999 (1999-03-01), pages 199 - 204, XP000857051, ISSN: 1434-6621 *
ESPINOSA ERIC ET AL: "Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gammadelta T cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 21, 25 May 2001 (2001-05-25), pages 18337 - 18344, XP002192586, ISSN: 0021-9258 *
MOSS RONALD B ET AL: "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 11-12, January 2000 (2000-01-01), pages 1081 - 1087, XP002153409, ISSN: 0264-410X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella

Also Published As

Publication number Publication date
WO2006067635A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE419008T1 (en) ADJUVANT COMPOSITION AND METHOD OF USE THEREOF
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CY2013036I1 (en) ANTI-NAISSERIA VACCINE COMPOSITIONS CONTAINING A COMBINATION OF ANTIGENS
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
DK1459766T3 (en) Adjuvant Compositions to Boost Immune Responses to Polynucleotide-Based Vaccines
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2006027685A3 (en) Glycosylceramide adjuvant for saccharide antigens
HK1168046A1 (en) Yeast-based vaccines as immunotherapy
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
ATE426412T1 (en) ADJUVANT INFLUENZA VACCINE
WO2006034414A3 (en) Loxapine analogs and methods of use thereof
NO20013749D0 (en) Immunological adjuvant compound
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2006107924A3 (en) Ehrlichia canis diva (differentiate infected from vaccinated animals)
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
NO20071523L (en) vaccinations
NO20050721D0 (en) HSP70 from Artherobacter
WO2007013893A3 (en) Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
EA200800917A1 (en) ADJUVANTA FOR VACCINES
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
CY1109349T1 (en) HSP60 FROM ARTHROBACTER
WO2010035119A3 (en) Vaccine adjuvants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05850789

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05850789

Country of ref document: EP

Kind code of ref document: A2